PR97794

MOUNTAIN VIEW, Calif., Sept. 13, 2022 /PRNewswire=KYODO JBN/ --

-- The proprietary platform is versatile, equally effective with different

cargoes, routes of administration

Turn Biotechnologies, a cell rejuvenation company developing novel mRNA

medicines to cure untreatable, age-related conditions, today announced it has

created a novel platform to safely and effectively deliver nucleic acid

therapeutics – a major expansion of the company's business.

The eTurna Platform(TM) is designed for the next generation of precision

medicine. It allows for a variety of cargoes requiring different routes of

administration to be finely tuned and targeted to specific tissue and cells.

The company will use the technology to deliver mRNA medicines developed using

the proprietary ERA(TM) (Epigenetic Reprogramming of Aging) platform.

ETurna(TM) can also carry other therapeutic cargoes through collaborations that

would unlock the potential of emerging therapeutics while fueling the delivery

platform's expansion.

"Our platform overcomes the ultimate barrier to mRNA medicine by making it

possible to deliver therapies precisely to their targets," said Anja Krammer,

Turn Bio CEO. "It is also extremely versatile, capable of encapsulating and

stabilizing mRNAs and large cargo to produce formulations that can be developed

for a wide array of therapies to transform how we treat disease."

Finding an effective carrier to deliver therapies to deliver nucleic acid and

other therapies in a targeted manner has been a challenge for researchers

worldwide. Traditional lipid carriers, designed primarily to deliver vaccines,

have proven inadequate for many applications because of their instability and

poor bioavailability, solubility and absorption in the body. These problems

threaten delivery challenges and potentially severe adverse effects for

patients.

Turn Bio's nanostructure carriers sidestep these issues, can be adapted for

individual therapies and tuned for use through different routes of

administration. The platform will produce unique formulations to precisely

steer the right mRNA or other cargo to the right organs, tissues and cell types.

eTurna was developed by Turn Bio's CMC team, which has nearly eight decades of

biotechnology experience, led by Mouhannad Jumaa, PhD, executive vice president

of pharmaceutical development/CMC.

Jumaa, a 20-year biopharmaceutical industry veteran, has invented and developed

several nano-lipids and liposomal drug products.  He has nine patents for his

development work, including products to stabilize and deliver encapsulated

drugs into targets for different routes of administration.

"eTurna caps a lifetime of work to develop new ways to deliver therapies more

precisely than ever," said Jumaa. "It overcomes the final obstacles that have

prevented transformational therapies from reaching patients. eTurna will help

to redefine patient care."

He has conducted research in Europe, the Middle East and United States, and

helped many biotechnology companies develop new products. The former head of

Pharmaceutics with Onyx/Amgen, Jumaa has worked with a variety of biotechnology

companies, including Roivant Sciences, Rain Therapeutics, and Cyclarity

Therapeutics. He has held senior scientific roles at Affymax, Rigel and 3M.

ABOUT TURN BIOTECHNOLOGIES

Turn Bio is a pre-clinical-stage company focused on repairing tissue at the

cellular level and developing transformative drug delivery systems. The

company's proprietary mRNA platform technology, ERA(TM), restores optimal gene

expression by combatting the effects of aging in the epigenome. This restores

cells' ability to prevent or treat disease and heal or regenerate tissue. It

will help to fight incurable chronic diseases. Its eTurna(TM) Delivery Platform

uses unique formulations to precisely deliver cargo to specific organs, tissues

and cell types.

The company is completing pre-clinical research on tailored therapies targeting

indications in dermatology and immunology, and developing therapies for

ophthalmology, osteo-arthritis and the muscular system. For more information,

see www.turn.bio.

FOR MORE INFORMATION, CONTACT:

Jim Martinez, rightstorygroup

jim@rightstorygroup.com or (312) 543-9026

Source - Turn Biotechnologies, Inc